Commodore Capital LP Inventiva S.A. Transaction History

Commodore Capital LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$5.61 - $12.15 $488,956 - $1.06 Million	-87,158 Reduced 33.18%	175,500 $995,000
Q1 2021 May 17, 2021	BUY	$12.55 - $19.0 $397,307 - $601,502	31,658 Added 13.7%	262,658 $3.86 Million
Q4 2020 Feb 16, 2021	BUY	$11.35 - $14.5 $2.62 Million - $3.35 Million	231,000 New	231,000 $3.35 Million

4.85M

Ticker IVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,134,200
Market Cap $92.7M
Description
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company als...

Get notified when there are updates to the investment portfolio of Commodore Capital LP, based on Form 13F filings with the SEC.

Stay updated on Commodore Capital LP with notifications on news.